Q2 revenue and EBITDA rise sharply; FY27 growth guidance retained

Management guided margin improvementOrder pipeline disclosedMulti-year targets disclosedInvestor Communications View source PDF Explain this filing

FABTECH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹125.61

prior close

₹124.31

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+2.5% vs market

Medical Equipment & Supplies peers, median of 10sector+1.2%+1.5% vs sector

On the reaction day the stock moved 2.5 pts more than Nifty Microcap 250 and 1.5 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.8

10m

+1.6

15m

+1.8

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7+0.3+2.5+1.2+1.5

Next day

+3.4+2.4+0.9+3.1+0.2

+7.3+3.6+3.7+4.2+3.1

+4.5pendingpending+2.7+1.8

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 10Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fabtech's Q2 FY27 revenue rose 22.8% from Q1 to INR 92.09 crore. EBITDA more than doubled to INR 15.57 crore, and margin rose to 16% from 9.5%. Adjusted PAT was INR 8.45 crore at a 9.2% margin. The order book exceeded INR 900 crore. Management retained FY27 revenue growth guidance of 25-30%, expects an 8-9% adjusted PAT margin, and sees 25-30% growth over 3-5 years.

Likely market impact

Stronger margins and a large order book support optimism, but project execution, geopolitical costs and pending European acquisition remain risks.